Elsevier

Contraception

Volume 71, Issue 2, February 2005, Pages 111-117
Contraception

Original research article
A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel

https://doi.org/10.1016/j.contraception.2004.08.017Get rights and content

Abstract

Objectives

To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.

Methods

In an open-label, randomized study, a dose-reduced oral contraceptive containing 20 μg EE and 100 μg LNG (20 EE/100 LNG) was compared with a reference preparation containing 30 μg EE and 150 μg LNG (30 EE/150 LNG). One-year data from 48 volunteers were obtained.

Results

We found a decrease of HDL2 cholesterol and increases of low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides in both treatment groups from baseline to the 13th treatment cycle. Although for four of six variables, the changes in the 20 EE group were lower compared with the 30 EE group, none of the differences between the two treatments were statistically significant.

The median values for the fasting levels of insulin, C-peptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles. While the glucose area under the curve (AUC) (0–3 h) was similar in both groups during the OGTT, the insulin AUC(0–3 h) was less increased in the 20 EE/100 LNG group compared with the 30 EE/150 LNG group. None of the differences between the treatment groups for any of the carbohydrate metabolism variables were statistically significant at any time point. Both study treatments were safe and well tolerated by the volunteers.

Conclusion

Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.

Introduction

Since the introduction of combined oral contraceptives (COCs) in the early 1960s, considerable efforts have been made to reduce the dose of the hormonal components in order to minimize the risk of adverse events (AEs). These efforts attempted to reduce the hormone content according to the principle “as little as possible, but as much as necessary.” In the 1990s, two new 20-μg ethinyl estradiol (EE)-containing preparations were introduced, one with the progestogen gestodene [1] and the other with desogestrel [2]. Both were derived from already marketed preparations containing 30 μg EE without reducing the progestogen dose. Another investigation, carried out with injectable contraceptives [3], suggested that the ratio between both hormonal components could influence the pharmacodynamic properties of the preparations. The new preparation tested in our study was also derived from an existing oral contraceptive containing 30 μg EE combined with 150 μg levonorgestrel (LNG), which was proven safe and effective for some decades [4]. However, in the new preparation, the dosages of both EE and LNG were reduced by one third. This dose reduction of both components maintains the original preparation's estrogen/progestogen ratio.

A large body of clinical data based on low-dose OCs containing 20 μg EE has become available in the past years. Despite some initial doubts about this reduction in the estrogen dose, it is generally acknowledged that 20 μg EE, in combination with a suitable progestogen, can provide effective contraceptive protection and clinically acceptable cycle control [1], [2], [5], [6], [7].

However, limited data on the effect of 20 μg EE COCs on metabolic variables is available [8], [9], [10]. The preparation investigated here is the first with a ‘balanced’ reduction, that is, a reduction of both hormonal components by one third. In this paper, we present the findings of the lipid and carbohydrate investigations. The results of the hemostatic variables will be published elsewhere. Recently, a very similar study was published which was conducted in The Netherlands [11].

Section snippets

Materials and methods

The study was performed as an open-label, randomized, prospective study at one center in Denmark (Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark) from December 1997 to April 2000 (study no. 96050). We compared the dose-reduced investigational preparation containing 20 μg EE and 100 μg LNG (20 EE) (Miranova, Schering, Berlin, Germany) with the reference containing 30 μg EE and 150 μg LNG (30 EE) (Microgynon, Schering). The

Results

A total of 70 women were randomized, 35 in each group. Sixty-nine received at least one dosage of treatment (full analysis population). Forty-nine women, 22 in the 20 EE/100 LNG group and 27 in the 30 EE/150 LNG group, were included in the PP population. The demographic characteristics of the two groups at baseline were well matched (see Table 1).

Discussion

This study was conducted to compare the differences in the effects of two COC preparations, one a dose-reduced version of the other, on lipid and carbohydrate profiles during 1 year of treatment in healthy volunteers.

The changes found in the lipid profile after 1 year of treatment are characteristic for low EE dose COCs [11], [14]: moderate, but measurable, increases in the values for LDL cholesterol, VLDL cholesterol and total triglycerides, and decreases in HDL2 cholesterol and Lp(a) were

Conclusion

Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new OC caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.

References (22)

  • N. Maitra et al.

    Progestogens in combined oral contraceptives for contraception

    Cochrane Database Syst. Rev.

    (2004)
  • Cited by (44)

    • Effect of oral contraceptive use on lipid profile in Korean women aged 35-55 years

      2012, Contraception
      Citation Excerpt :

      Furthermore, several epidemiological studies have indicated that exposure to OCs may alter lipid metabolism. OCs have been reported to cause alterations in the serum concentrations of some lipid compounds, including total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides, causing dyslipidemia in various study designs of short- and long-term administration modalities [11–14]. However, findings from epidemiological studies of the association between OCs and lipid profile have been less consistent according to the population studied; different levels of total cholesterol, HDL-C, LDL-C and triglycerides have been reported following the administration of OCs.

    • The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism

      2012, Contraception
      Citation Excerpt :

      Obese and normal-weight participants experienced similar changes in all of these measures. This study agrees with others that combination OCs containing norgestrel-type progestins are associated with changes in carbohydrate metabolism that are too small to be clinically significant [23,24]. More recently, some have argued for a more strict definition of glucose intolerance [22]; still, with these definitions, obese women experience changes similar to normal-weight women.

    • Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies

      2011, Endocrinology and Metabolism Clinics of North America
    View all citing articles on Scopus
    View full text